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Abstract
Mass production and use of antibiotics has led to the rise of resistant bacteria, a problem
possibly exacerbated by inappropriate and non-optimal application. Antibiotic treatment
often follows fixed-dose regimens, with a standard dose of antibiotic administered equally
spaced in time. But are such fixed-dose regimens optimal or can alternative regimens be
designed to increase efficacy? Yet, few mathematical models have aimed to identify optimal
treatments based on biological data of infections inside a living host. In addition, assump-
tions to make the mathematical models analytically tractable limit the search space of possi-
ble treatment regimens (e.g. to fixed-dose treatments). Here, we aimed to address these
limitations by using experiments in a Galleria mellonella (insect) model of bacterial infection,
to create a fully parametrised mathematical model of a systemic Vibrio infection. We suc-
cessfully validated this model with biological experiments, including treatments unseen by
the mathematical model. Then, by applying artificial intelligence, this model was used to
determine optimal antibiotic dosage regimens to treat the host to maximise survival while
minimising total antibiotic used. As expected, host survival increased as total quantity of
antibiotic applied during the course of treatment increased. However, many of the optimal
regimens tended to follow a large initial ‘loading’ dose followed by doses of incremental
reductions in antibiotic quantity (dose ‘tapering’). Moreover, application of the entire antibi-
otic in a single dose at the start of treatment was never optimal, except when the total quan-
tity of antibiotic was very low. Importantly, the range of optimal regimens identified was
broad enough to allow the antibiotic prescriber to choose a regimen based on additional cri-
teria or preferences. Our findings demonstrate the utility of an insect host to model antibiotic
therapies in vivo and the approach lays a foundation for future regimen optimisation for
patient and societal benefits.
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Author summary
Research into optimal antibiotic use to improve efficacy is far behind that of cancer care,
where personalised treatment is common. The integration of mathematical models with
biological observations offers hope to optimise antibiotic use, and in this present study an
in vivo insect model of systemic Vibrio infection was used for the first time to determine
critical model parameters for optimal antibiotic treatment. By this approach, the optimal
regimens tended to result from a large initial ‘loading’ dose followed by subsequent doses
of incremental reductions in antibiotic quantity (dose ‘tapering’). The approach and find-
ings of this study opens a new avenue towards optimal application of our precious antibi-
otic arsenal and may lead to more effective treatment regimens for patients, thus reducing
the health and economic burdens associated with bacterial infections. Importantly, it can
be argued that until we understand how to use a single antibiotic optimally, it is unlikely
we will identify optimal ways to use multiple antibiotics simultaneously.
Introduction
The increased availability of antibiotics has led to the overuse, and often inappropriate use, of
these substances. This has resulted in bacterial diseases such as gonorrhoea, sepsis and tuber-
culosis becoming increasingly difficult to treat due to the emergence of multi-drug resistant
strains [1–5]. Resistant bacteria pose significant health and economic burdens that has necessi-
tated research into preventing their spread in attempts to prolong antibiotic effectiveness.
Unfortunately, research indicates that the fight against antibiotic resistance will not be won by
simply restricting when antibiotics are prescribed, therefore we must consider how they are
prescribed [6–8].
Bacterial antibiotic resistance is not only of great concern for human patients, but it also
has a significant impact in agriculture [9], aquaculture [10–11], horticulture [12], and the natu-
ral environment [13]. With the growth of the human population and the increased demand
for animal protein in particular, the use of antibiotics in food production continues to increase
[14]. Antibiotics are used extensively in these industries to treat infections and prevent dis-
eases. Due to the importance of antibiotics for human and animal health, many countries have
tight legislation surrounding the use of antibiotics within livestock production [15]; however,
enforcement of such legislation still represents a major challenge in some territories.
The ‘prudent’ use of antibiotics has long been recommended as a way to slow the spread of
antibiotic resistance [16]. However, for this to be fully effective, the treatment regimens under
which they are administered should be optimal. Optimal antibiotic treatment strategies using a
single antibiotic consist primarily of two variables: the dose and the duration of treatment. For
most antibiotics, the drug developer identifies a treatment regimen which then is implemented
by clinicians and veterinary surgeons when prescribing these antibiotics [17]. Conventional
treatment regimens usually consist of a fixed dose administered typically equally split in time
for a specified duration, e.g. 100 mg (or one tablet) given once per day for 7 days. Pharmacoki-
netics and pharmacodynamics studies of target populations are used to determine the dose
and duration for these treatment regimens. However, one limitation of this approach is that it
only provides information for the regimen being analysed and offers no indication for other
potential regimens [18]. While these fixed-dose treatment regimens may be effective, they may
not be the optimal dose or duration at which to administer the antibiotic most efficaciously or
to prevent the emergence and spread of resistance [19].
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The use of mathematical modelling in disease modelling and antibiotic resistance research
has grown considerably over the past few decades and is now an invaluable tool [20]. Despite
this, there is still little consensus on how individual antibiotic dosage regimens should be
applied. D’Agata et al. [21] examined a series of models that included an immune response
and a constant concentration of antibiotic (when present). These authors concluded that one
of the most important factors was the early initiation of antibiotic treatment; however, they
also argued that shorter antibiotic treatment durations resulted in the survival and selection of
resistant strains [21]. Geli et al. [22] incorporated pharmacodynamics into their mathematical
model by considering the antibiotic-induced death rate to be a function of the concentration
of antibiotic present, although the concentration was modelled as a (non-dynamic) step func-
tion. These authors found that all antibiotic use increased the selection of resistance, regardless
of the treatment regimen, although this was minimised for shorter durations of treatment,
which also saw the time with symptoms decrease [22]. Ankomah and Levin [23] addressed the
issue of a constant concentration of antibiotic by assuming that when antibiotics were not
added to the system the concentration of antibiotic declined exponentially. They showed that
under most conditions, high dose therapy is more effective than more moderate dosing to
clear the infection and decrease the likelihood of emergence of antibiotic resistance; although
these authors acknowledge that antibiotics can produce unwanted side-effects at greater con-
centrations [23]. Gjini and Brito [24] investigated the concept of adaptive treatments, whereby
treatments are linked to bacterial load, further demonstrating that classical treatments (fixed
dose and duration) are sub-optimal [24].
Given the increasing number of studies aiming to optimise antibiotic dosage regimens,
advanced computational search algorithms, such as Genetic Algorithms (GA) [25], are signifi-
cantly under-utilised in this field. This is in contrast to areas such as cancer chemotherapy
where such approaches have been used for more than a decade [26–27]. GAs, which are a form
of Evolutionary algorithms, allow a much wider search space to be studied and allows the
relaxation of assumptions such as constant concentration of antibiotics, or fixed daily doses.
They are also adept for studying multi-objective optimisation problems, where the quality of a
solution is defined by its performance in relation to several, often conflicting, objectives. Most
real-world optimisation problems are multi-objective. However, they are traditionally trans-
formed into a single-objective function, by means of a weighted sum of sub-functions, in order
to make optimisation tractable. This approach suffers from a number of drawbacks; it assumes
that we can capture preferences (weights), even before knowing the possible range of feasible
solutions; and that these preferences remain static. Evolutionary algorithms have proven suc-
cessful in finding high-quality solutions in high-dimensional spaces with difficult features such
as constraints and discontinuities, and are currently the state of the art in many multi-objective
optimisation problems [28].
Paterson et al. [29] was first to apply a GA to antibiotic dosing, allowing the size of each
individual dose within a treatment regimen to vary. These authors found that tapering the
antibiotic dosages, with a high first dose followed by subsequent decreasing doses, maximised
the survival rate of hosts. Khan and Imran [30] confirmed these findings in a similar model,
taking an optimal control theory approach. A second study using a GA [31] investigated a
model of granulomas in a Mycobacterium tuberculosis infection, identifying the dose size and
the dosing frequency to eradicate the bacteria quickly while keeping individual antibiotic dos-
ages low.
Many of these previous studies are built around theoretical systems, with arbitrarily created
parameter sets. There is little to no evidence at present whether these proposed treatment regi-
mens will remain optimal inside an infected living host. Furthermore, there are very few
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mathematical models of antibiotic treatment systems that have been parameterised using bio-
logical data, and even the majority of these rely on in vitro studies [32–35].
There are two primary aims for this present study: firstly, to create and parameterise a
mathematical model using host survival data from biological experiments in an infected living
organism that can be treated with antibiotics; this mathematical model will be tested and vali-
dated by a set of follow up biological experiments. Secondly, the GA will be applied to this vali-
dated model to derive optimal treatment regimens, initially with the objective of maximising
host survival and, subsequently, maximising host survival while minimising the total amount
of antibiotic used. Due to the novel approach, which combines in vivo experiments with math-
ematical modelling and artificial intelligence, we consider only a scenario encompassing a sin-
gle antibiotic used against only a single strain, and the inclusion of multiple strains of varying
susceptibility to the antibiotic is reserved for future study.
Animal models such as mice and rats are used in infection and treatment studies typically
as a surrogate for humans, but despite the importance of such in vivo experiments there is a
strong movement to reduce the number of vertebrates used in experimentation. Thus, less sen-
tient alternative hosts such as insects are used increasingly for in vivo studies due to their
greater ethical acceptance and low cost. In particular, the larva of the greater wax moth Galleria
mellonella has become a popular choice amongst infection researchers and it has also been
used successfully to assess the efficacy of antibiotic therapy in vivo [36–37]. Therefore, this
insect host offers the ability to assess the in vivo efficacy of different antibiotic regimens against
systemic bacterial infections. In earlier work, G. mellonella was demonstrated to be a suitable
alternative host for studying the virulence of Vibrio anguillarum, an opportunistic bacterial
pathogen of fish that causes sepsis in the host [38]. Virulent isolates of V. anguillarum can rep-
licate inside the insect but antibiotics to which the bacterium is susceptible can be adminis-
tered to save the host from a lethal inoculum of bacteria [38]. Notably, V. anguillarum was
recently reported to be responsible for a lethal human infection [39]. Therefore, this host–




Reagents, culture media and antibiotics. All chemicals and reagents were purchased
from Sigma-Aldrich Ltd (Gillingham, UK) unless stated. All solutions were made with distilled
water. Phosphate-buffered saline (PBS) was prepared according to Desbois and Coote [36].
Bacteria were cultured routinely on 1.5% (w/v) NaCl-supplemented tryptone soy agar (TSA;
Oxoid, Basingstoke, UK) and broth (TSB; Oxoid), while Mueller-Hinton broth (MHB; Oxoid)
supplemented with 2% (w/v) NaCl was used for minimum inhibitory concentration (MIC)
determinations. Water, PBS and culture media were sterilised by autoclaving at 121˚C for 15
min. Tetracycline hydrochloride (TET) was dissolved in distilled water, filter-sterilised (0.22 μ
polyethersulfone; Millipore, Watford, UK) and then diluted to required concentration in PBS.
Fresh stocks of TET were prepared daily.
Bacteria. V. anguillarum serotype O1 isolate Vib 79 (LMG 12101) [40] was kept routinely
at -70˚C in 15% (v/v) glycerol. Before use, bacteria were recovered initially onto agar, incu-
bated at 22˚C for 48 h, and then single colonies inoculated into broth. Cultures were incubated
(22˚C; 150 rpm; 12 h) until mid- to late-exponential phase and then bacterial cells were har-
vested by centrifugation (2700 x g; 15 min; 4˚C). The cell pellet was washed by resuspension in
PBS, centrifuged as before, re-suspended again in PBS, and then cell density determined by
measuring absorbance at 600 nm (A600). Bacterial suspensions were diluted with PBS to 1×107
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CFU/mL, and all inoculums were serially diluted in PBS in quadruplicate and plated on TSA
to confirm cell density.
Insects. G. mellonella larvae in their final instar stage were purchased (approximately 220
mg each; UK Waxworms Ltd, Sheffield, UK), stored in the dark at 4˚C, and used within 14
days. A 50-μL Hamilton syringe (Sigma-Aldrich Ltd) was used for all injections of bacterial
suspension, TET solution or PBS.
In vitro minimum inhibitory concentration. To identify a suitable TET dose to adminis-
ter to infected G. mellonella larvae in an attempt to rescue them from a lethal inoculum of V.
anguillarum, minimum inhibitory concentrations were determined according to a method
modified from the Clinical and Laboratory Standards Institute standard [CLSI; 41]. Briefly, the
wells in the last column of a flat-bottomed polystyrene 96-well microtitre plate (Sarstedt, Nüm-
brecht, Germany) were dispensed with 100 μL MHB containing antibiotic at double the great-
est desired concentration for the assay. Two-fold dilutions were performed across the plate in
fresh MHB and the final column contained just 100 μL MHB (no antibiotic control). Then,
5 μL of V. anguillarum suspension at 1×107 CFU/mL was added to each well of duplicate rows
on the plate. Microtitre plates were incubated (22˚C; 180 rpm; 24h) and then the wells were
examined by eye for growth. The MIC was recorded to be the lowest concentration of antibi-
otic at which no turbidity is observed.
Antibiotic treatment experiments. All experiments were completed in triplicate using
larvae from different batches. Initial antibiotic experiments used groups containing 15 larvae
(total n = 45) while model validation experiments used groups of 30 larvae (total n = 90). First,
10 μL of bacterial suspension was injected into larvae via the last left proleg before treatment at
2 h, 24 h and 48 h with 10 μL of TET solution, diluted to various concentrations in PBS,
according to a published protocol [36]. The syringe was cleaned between experiments and
treatment groups with consecutive washes of 1% (w/v) sodium hypochlorite, 70% ethanol and
sterile water. A positive control group was injected with bacterial suspension, and PBS only
instead of antibiotic. Three negative control groups were always prepared: one group that
underwent no manipulation to control for background larval mortality (no manipulation con-
trol), a second group (uninfected control) that was injected with PBS only at initial challenge
and all treatment time points, and a third group which assessed for the toxicity of the TET
treatment by inoculation with the greatest antibiotic concentration used at each time point.
There was never more than one death per control group per experiment. Larvae were stored in
Petri dishes in the dark at 15˚C for up to 192 h. Larvae were inspected every 24 h so that per-
centage survival could be calculated for each group; larvae were considered dead if they did
not move after being touched with a sterile inoculation loop. This process was further refined
for the model validation experiments when larvae were examined for movement under an
Olympus VMZ 1× 4× VM stereo microscope (Tokyo, Japan).
Half-life of tetracycline. Inhibition of V. anguillarum growth by wax moth haemolymph
spiked with TET was examined in vitro by disk diffusion assay to determine the relationship
between TET concentration in haemolymph and the diameter of a growth inhibition zone. A
single colony of V. anguillarum was added to 2 mL of PBS and vortexed for 30 s to suspend the
bacteria. Bacterial lawns were prepared on 1.5% (w/v) NaCl-supplemented TSA plates by
spreading 50 μL of bacterial suspension across the agar surface with a sterile cotton wool swab
before drying for 1 h at room temperature. The haemolymph (ca. 5–20 μL from each animal)
from 15 unmanipulated larvae was harvested according to McMillan et al. [38] and pooled in a
bijou bottle on ice. Aliquots of haemolymph were prepared on ice to contain concentrations of
TET between 0.625 mg/L and 40 mg/L, as described in MIC method (above). Then, 20 μL of
each TET dilution was pipetted onto separate sterile antibiotic assay disks (Whatman 6 mm;
GE Healthcare Life Sciences, Little Chalfont, UK). Once dry, the disks were placed onto the
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agar plates that had been inoculated with V. anguillarum, and then incubated (22˚C; 24h).
Then the diameters of the zones of inhibition were measured with calipers. This experiment
was completed in triplicate. To estimate the decay rate of TET in vivo, half-life experiments
were completed in wax moth larvae. TET was inoculated into wax moth larvae at 5 mg/kg.
Haemolymph was harvested from larvae at 0.25 h, 0.5 h, 1 h, 1.5 h, 2 h, 4 h, 6 h, 8 h, 24 h and
30 h, then transferred onto antibiotic assay discs and tested for growth inhibition as described
above. This experiment was performed in triplicate and larvae injected with PBS only were
included as a negative control.
Mathematical modelling
From here on in, for simplicity, we refer to G. mellonella larvae as the ‘host’, V. anguillarum as
the ‘bacteria’ and TET as the ‘antibiotic’.
Bacteria. We assumed the bacteria population, with density given by B(t), is identical in
terms of its antibiotic sensitivity–by which we mean the concentration of antibiotic required to
kill off the population. The two actions in this model were: (i) replication, creating new bacterial
cells, with rate R+, increasing the bacterial population; and (ii) the death of bacterial cells, R−,
due to either the host immune system or by the antibiotic, reducing the bacterial population.
For the bacterial population, the replication process was modelled by an exponential growth
term (we initially tried a logistic growth function, but upon initial parameterising the model the
carrying capacity was estimated to be 1012, which is considerably in excess of the bacterial load
of 109 at which the host tends die [38]). The death rate due to the immune system was modelled
by a saturating function, and the death rate due to the antibiotic was modelled by a sigmoidal
function, where A is the quantity of antibiotic present to act against the bacterium causing the














The number of bacteria was modelled using a Markov chain approach, specifically the Gil-
lespie Algorithm [42] (described below). Due to the high population size of bacteria, up to 109,
the standard Gillespie Algorithm would have a high run-time (as the time between each indi-
vidual event would be close to zero). Hence, we took an approximation of the Gillespie Algo-
rithm, known as Tau-leaping [43]. Following preliminary runs of the mathematical model, we
settled on a fixed time step of τ = 0.25 (15 minutes), and updated the number of bacteria using
Eq (2)
Bðt þ tÞ ¼ BðtÞ þ PðtRþðtÞÞ   PðtR  ðtÞÞ ð2Þ
where P(τx(t)) is a Poisson distributed random variable with mean τx(t). Initially, the bacteria
population was B(0) = 105, matching the biological experiments. To model host heterogeneity,
for each run of the mathematical model, r and m were drawn from a normal distribution with
means rμ and mμ respectively, and a shared standard deviation v, i.e. r~N(rμ,v) and m~N(mμ,
v).
Antibiotic
The antibiotic concentration was based on a standard pharmacokinetic / pharmacodynamics
(PK/PD) approach, where A is the quantity of antibiotic present to act against the bacterium
causing the infection, and a is the decay rate of the antibiotic. We modelled this using the
PLOS COMPUTATIONAL BIOLOGY Optimising antibiotic treatment regimens
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commonly taken approach [44], with equations shown in (3):
Aðt þ tÞ ¼ AðtÞ þ PðtaAðtÞÞ ð3Þ
As the time t passed a dosage time point, ti = 2h, 24h, 48h, the next dose of antibiotic, di, was
applied to the system. Initially, we assumed there was no antibiotic in the host, so A(0) = 0.
As this was a stochastic model, the behaviour of the antibiotic and bacteria population size
changed with each run. For this reason, we carried out 5000 runs of the model, and counted the
number of runs where treatment was a ‘success’: a model run was a ‘success’ if the host survived
to 192 h, as measured by the bacterial population size staying below a threshold, i.e. B(t)<Bdead
for all t2[0,192]; whereas a model run was a ‘failure’ if the host died, if the bacterial population
exceeded the threshold, i.e. B(t)>Bdead for any t2[0,192]. McMillan et al (2015) found in their
experiments that the host (the larvae) died when the bacterial densities reached approximately 109
[38]; this provides a value for the ‘death threshold’ Bdead of 109. The success of an antibiotic treat-
ment was then measured by the fraction of runs where the host survived to 192 h, denoted Nsurv.
The parameter definitions are given in Table 1.
Computational Optimisation
Genetic Algorithms (GA) were proposed by John Holland in the early 1970s [25]. They belong
to the larger class of evolutionary algorithms, which generate solutions to optimisation prob-
lems using techniques inspired by natural evolution, such as inheritance, mutation, selection
and crossover [45]. GAs have previously been used to generate treatment schedules for chemo-
therapy of cancer patients [26–27], but have rarely been used in antibiotic therapy [29,31].
Despite being a randomised search GAs are by no means random, instead they use historical
information to direct the search into the region of better performance within the search space.
Here, the GA was used for two purposes:
Parameterisation. To parametrise the mathematical model, we used the GA to find a set
of parameters that allowed the model to best match the biological data. The GA generated sets
of parameter values for rμ, v, mμ, n, a, a1, a2 and k, represented by a vector of real numbers. For
each set, the GA ran the mathematical model 5000 times, and computed how well the mathe-
matical model fitted the data, as measured by a least squares approach calculating the differ-
ence between host survival rates at each 24-h interval from the mathematical model and the




















Table 1. Parameter definitions. The parameter values were those found during the optimisation process in the
Results section.
Parameter Definition Value
rμ Average Replication rate of bacteria 0.4779
mμ Co-efficient for the host immune response 0.6772
n Hill co-efficient in the immune response 0.9193
v Standard deviation for host heterogeneity 0.0525
a1 Maximum kill rate of antibiotic 0.7281
a2 Level of antibiotic giving half max kill rate 0.1910
k Hill co-efficient in AB induced death. 2.9821
a Decay rate of antibiotic (half-life = 5.9hrs) 0.1174
Bdead Bacterial load at which the host dies [38] 109
https://doi.org/10.1371/journal.pcbi.1008037.t001
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The first term compared the model to the data in McMIllan et al. [38], summarised in the
Supporting Information (S1 Table), where hosts were infected but not treated with antibiotic,
and host survival data measured at 24-h intervals from 0 h to 120 h. The second term com-
pared the mathematical model to the biological data from Table 2, where hosts were infected
and treated with antibiotic, and host survival measured at 24-h intervals from 0 h to 192 h.
Optimising dosage regimens. Antibiotic regimens are represented by dosage vectors (d1,
d2, d3,. . .), where di denotes the quantity of antibiotic (measured in mg) to be given at time ti.
The GA aimed to find the optimal dosage vector that minimised our objective function, which
comprised of up to two components: first, to maximise the number of runs of the mathemati-
cal model where the host survived the infection, i.e. B(t)<Bdead for all t, denoted Nsurv; second,
to minimise the total amount of antibiotic used, as measured by the sum of the entries in the
dosage vector, ∑idi. In addition, we had constraints: ∑idi�0.9 mg, where 0�di�0.9 (except for
the final section in the results, ‘(iv) Maximise survival vs. minimise total antibiotic’, where we
increased the total quantity of antibiotic). For each regimen, the GA ran the mathematical
model 5000 times, with a population size of 50 potential solutions (dosage vectors), for 80 gen-
erations and the whole process was repeated 50 times. At the end of the complete GA run, we
produced 50 sets (one from each GA run), each containing 50 possible solutions (dosage vec-
tors). The run lengths, generations and population sizes were arrived at from prior calibration
of the configuration that confirmed that minimal further improvement in performance was
gained by increasing these values.
Results
Initial antibiotic experiments
Initially the larvae hosts were treated with 0.9 mg of tetracycline, split into fixed dosages at
24-h intervals, either: all 0.9 mg in one dose at 2 h; split into two equal doses of 0.45 mg each at
2 h and 24 h; split into three equal doses of 0.3 mg each at 2 h, 24 h and 48 h. The survival rates
of the larvae are shown in Table 2.
Half-life experiments. To gain a more accurate estimate for the decay rate of the antibi-
otic (TET), the concentration of antibiotic activity in the haemolymph was measured over
time (Fig 1, with exact values in Supporting Information (S2 Table). Fitting a curve to these
data, along with the 95% confidence intervals, provided an estimation of the half-life of TET to
be approximately 5.89 h, with a confidence interval of 3.72–9.26 h, which is in accordance with
previous biological estimates [46]. This provided an appropriate interval for the decay rate of
the antibiotic, a. (Following subsequent application of the GA, a half-life of 5.90 h was settled
upon.)
Table 2. Host survival at the end of each 24-h interval for different ‘fixed dose’ treatments, i.e. 0.9 mg either administered as a single dose, or split equally over 2
days, or split equally over 3 days (n = 45). PBS = phosphate-buffered saline; Vib 79 = V. anguillarum (bacterium).
group infected treatment (mg/kg) Host survival (proportion of host alive at each measure)
0 h 2 h 24 h 48h 24h 48h 72h 96h 120h 144h 168h 192h
unmanipulated - - - - 1 1 1 1 1 1 1 1
PBS only PBS PBS PBS PBS 1 1 1 1 1 1 1 1
antibiotics only PBS 0.9 0.45 0.3 1 1 1 1 1 1 1 1
positive control Vib 79 PBS PBS PBS 1 0.02 0 0 0 0 0 0
0.9 mg Vib 79 0.9 PBS PBS 1 1.00 0.98 0.82 0.69 0.62 0.53 0.53
0.9 mg Vib 79 0.45 0.45 PBS 1 1.00 0.89 0.78 0.67 0.58 0.42 0.38
0.9 mg Vib 79 0.3 0.3 0.3 1 0.96 0.44 0.27 0.13 0.09 0.04 0.04
https://doi.org/10.1371/journal.pcbi.1008037.t002
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Parameterisation of the mathematical model
The survival rates in Table 3, and the survival rates from McMillan et al. [38] summarised
in Supporting Information (S1 Table), were used to parameterize rμ, v, mμ, n a, a1, a2 and
k. The GA showed strong convergence and provided a set of parameter values that best fit
the data. The model with these parameters showed a reasonable fit with the biological
data (Table 2) when mean host survival over time was plotted (Fig 2). (In the Supporting
Information (S1 Fig), the bacteria densities within the host are plotted over time for case
the infected host is not treated with antibiotics. Comparing the model output with the
biological data from [38] shows that the model’s maximum growth rate of bacteria is
reasonable.)
Fig 1. Decay rate of the antibiotic (TET) over time in G. mellonella host. Biological data of the decay rate of the
antibiotic over time in G. mellonella (red points); and fitted curves for the experimental data (black lines) and the
estimate for the half-life of the antibiotic (blue lines). The black and blue dotted lines represent the respective 95%
confidence intervals.
https://doi.org/10.1371/journal.pcbi.1008037.g001
Table 3. Host survival from the biological validation experiments. Host survival was recorded at 192 h for five dif-
ferent antibiotic treatment regimens, with both the ‘raw’ data given, along with the ‘normalised’ data, whereby host sur-
vival for four of the treatments were increased by 0.28 to bring host survival for (0.45,0.45) and (0.9,0) treatments in
line with those in the initial experiments, in Table 2. (n = 90.) Full data in the Supporting Information (S3 Table).
infected treatment (mg/kg) Host survival at 192h
0 h 2h 24h Raw Normalised
Vib 79 0.20 0.70 0 --
Vib 79 0.45 0.45 0.10 0.38
Vib 79 0.56 0.34 0.21 0.49
Vib 79 0.76 0.14 0.26 0.54
Vib 79 0.9 PBS 0.24 0.52
https://doi.org/10.1371/journal.pcbi.1008037.t003
PLOS COMPUTATIONAL BIOLOGY Optimising antibiotic treatment regimens
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Validating the Model
To determine the effect of the size of the first dose, and whether a bigger first dose leads to a
higher survival, we consider a general two-dose strategy of the form (d1, 0.9−d1), with dose d1
at 2 h and the second (remaining) dose at 24 h. This strategy used 0.9 mg of antibiotic in total.
Our parameterised mathematical model was run for values of d1 from 0 to 0.9, in increments
of 0.01, with survival rate recorded at 192 h (Fig 3). There is a strong correlation between the
Fig 2. Comparison of mathematical model and experimental results for survival rates for different ‘fixed dose’ treatments, with 0.9 mg either
administered as a single dose, or split equally over 2 days, or split equally over 3 days: (A) 0.9 mg administered at 2 h; (B) 0.45 mg administered
at 2 h and at 24 h; (C) 0.3 mg administered at 2 h, 24 h and 48 h. n = 45 for biological experiments; n = 5000 for mathematical model.
https://doi.org/10.1371/journal.pcbi.1008037.g002
Fig 3. Survival rates at 192 h for various first doses, d1; where the second dose is (0.9−d1). The mathematical model
results are in black; blue circles represent the initial biological experimental data (Table 2), and green circles are the
additional biological experiments (Table 3). Red circles represent the normalised data from Table 3 (with each of the
four points increased by 0.28). (The model runs for these solutions were increased to 10000 to confirm the accuracy of
the results).
https://doi.org/10.1371/journal.pcbi.1008037.g003
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first dose and host survival, with a Spearman Rank co-efficient of 0.96. There is a small drop in
host survival for first doses d1 between 0.65 and 0.85, however, this is only small.
To validate the mathematical model, five two-dose treatments were then chosen, and biologi-
cal experiments of these treatments were carried out for n = 90 larvae (Table 3; the full data set,
with survival at the end of each 24-h interval is given in the Supporting Information (S3 Table)).
The survival rates in these in vivo experiments (Table 3) were significantly lower than those
of the initial experiments (Table 2), and a direct comparison of the regimens (0.9,0) and
(0.45,0.45) showed a consistent drop of ~0.28 in the survival rate at 192 h. This is likely due to
seasonal variation in the condition of the larvae, which can occur [47–48]. Therefore, for
modelling purposes, we normalised the survival rate of the regimens (0.45,0.45), (0.56,0.34),
(0.76,0.14) and (0.9,0) by increasing the survival rates universally at 192 h by 0.28. Comparing
these new scaled survival rates to our mathematical model (Fig 3) showed that the model suc-
cessfully predicted the survival rates of the previously untested regimens.
Optimisation of treatment regimens
We applied the GA to the parameterised mathematical model to search for optimal antibiotic
dosage regimens to maximise host survival at 192 h under various conditions:
i. Daily dose treatments: Taking a daily dose treatment strategy, with doses at 2 h, 24 h, 48
h and 72 h, we found that to maximise host survival at 192 h, using 0.9 mg of TET, the
best strategy was to administer all 0.9 mg at 2 h, with 0 mg at the remaining dose times.
This gave a host survival rate at 192h of 0.566.
ii. Two-dose, variable timings: Next, we allowed the timing of the doses to vary, initially
limiting the solutions to two-dose treatments, whereby a dose d1 is given at 2 h, and a sec-
ond (remaining) dose of 0.9-d1 is given at t2 hours. Given we only had two variables, d1
and t2, we carried out a brute force (exhaustive) search for d1 between 0 and 0.9 (in inter-
vals of 0.01), and t2 at hourly intervals between 3 h and 24 h. In Fig 4, we plot host survival
Fig 4. Two-dose treatment regimen with the first dose d1 is taken at 2 h and the second dose 0.9- d1 at t2 h. Host
survival at 192 h is plotted against the size of the first dose d1: and the time of the second dose t2. Model runs = 10000.
https://doi.org/10.1371/journal.pcbi.1008037.g004
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at 192 h against the time of the second dose t2, and the size of the first dose d1. We found
that the optimal strategy was to administer a first dose of 0.54 mg of TET at 2 h and a sec-
ond dose of 0.36 mg at 11 h, giving a survival rate at 192 h of 0.795. This is significantly
greater than the survival rate of 0.566 for administering all 0.9 mg of TET in a single dose
at 2 h.
iii. Multiple-doses, variable timings: We extended the search to find the optimal treatment
regimen, using 0.9 mg of antibiotic, by allowing any number of doses. A GA was applied
to this problem, allowing the individual dosage quantities and timings of these doses to
vary, to find the regimen that maximised host survival at 192 h. We found the optimal
regimen was a four-dose strategy, giving: 0.43 mg at 2 h, 0.22 mg at 7.1 h, 0.13 mg at 11.7
h, and 0.13 mg at 16.8 h, which gave a host survival rate of 0.803. (Note, total antibiotic
adds to 0.91 mg due to rounding.) Given this is a stochastic model, it would be difficult to
test experimentally whether the improvement over the two-dose treatment above, with
survival of 0.795, is significant.
iv. Maximise survival vs. minimise total antibiotic: Taking a multi-objective approach, we
aimed to maximise host survival at 192 h while minimising the total quantity of antibiotic
used. Again, we allowed both the individual doses and the timing of these doses to vary.
In Fig 5, Pareto Front is plotted–in the context of multi-objective optimisation, a Pareto
Front is a set of non-dominated solutions, which are considered optimal if no objective
can be improved without sacrificing at least one other objective; this was done using a
well-known GA suited for multiple objectives, NSGA-II [49]. Each point represents the
host survival rate and quantity of antibiotic used, assuming that that the amount of antibi-
otic is used optimally. Before deriving solutions for a particular regimen, we had to ensure
that the results were consistent and therefore we repeated the optimisation process over
Fig 5. (A) Combined Pareto Fronts for 50 repeat runs; (B) subset of points along the upper edge of combined Pareto Fronts in (A). Both graphs
show the trade-off between the total amount of antibiotic used in a treatment regimen and maximum host survival at 192 h. The colours of the
points represent the number of (non-zero) antibiotic doses used to achieve that optimal point. Population = 50, generations = 80, model
runs = 5000, repetitions = 50.
https://doi.org/10.1371/journal.pcbi.1008037.g005
PLOS COMPUTATIONAL BIOLOGY Optimising antibiotic treatment regimens
PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1008037 August 3, 2020 12 / 20
50 independent runs. The combined set of Pareto Fronts for these 50 optimisation runs is
given in Fig 5A and shows a consistency across the repeat runs with regard to the trade-
off between total antibiotic use and host survival at 192 h. From this set of 50 repeat runs,
we extracted the points along the upper edge of the combined Pareto Fronts to produce a
final composite Pareto Front that is optimal across all 50 runs (Fig 5B). There exists a
strong, non-linear, positive correlation between survival and the total quantity of antibi-
otic used. In fact, for total antibiotic dosage of between 0.56 mg and 0.95 mg, there is a
very strong linear correlation (r = 0.997), with a gradient of 2.12, i.e. every 0.1 mg increase
in antibiotic gives an increase in host survival at 192 h of 0.212. In addition, we saw
almost distinct boundaries between where the optimal regimen involved increasing the
number of doses: a single (initial) dose when using less than 0.49 mg, two-doses when
using between 0.49 mg 0.64 mg in total, three-doses when using between 0.64 mg and 0.9
mg in total, and four-doses when using more than 0.9 mg in total.
To understand the form of the optimal dosage vectors in the Pareto front, we explored the
treatment regimens that were found by the GA and extracted the best regimen for a particular
objective. Table 4 shows the solutions from Fig 5B where we consider treatments that have a
survival rate at 192 h of at least (a) 0.9, and (b) 0.99 for different objectives. These objectives
were: (i) the least total antibiotic used (i.e to minimise ∑di); (ii) the least number of doses (i.e.
least number of non-zero entries in dosage vector); (iii) the lowest maximum dose (i.e. to min-
imise max(di)); (iv) the earliest final dose (i.e. to minimise di).
All the treatments in Table 4 have a similar pattern in that the first dose is the largest dose,
with many of the subsequent doses decreasing throughout, e.g. (0.48, 0.28, 0.24). There is also
an appearance of possible additional trade-offs. For example, comparing row 1 and row 5 in
Table 4, in reducing the maximum concentration of individual doses may require an increase
in the total quantity of antibiotic used and an increase in the duration of treatment. Calculating
the Spearman Rank co-efficient for Fig 5B, we get of 0.55, indicating that there is no longer a
strong correlation between the first dose and host survival; given the wider range of treatments
in terms of number of doses (e.g. more, smaller doses) and timings (e.g. smaller doses closer
together), this is to be expected.
Table 4. Optimal treatment regimens from within the Pareto Front (Fig 5B) for different criteria, given host survival at 192 h of at least (a) 0.9, or (b) 0.99. (�Only
4-dose treatments were found along the upper edge of Pareto Front with host survival more than 0.99).
Objective Dose 1 Dose 2 Dose 3 Dose 4 Total AB Survival at 192h
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Discussion
The first aim of this study was to build and parameterise a mathematical model that accurately
represents a systemic bacterial infection (V. anguillarum) in an in vivo host (G. mellonella) that
can be treated with different fixed-dose antibiotic regimens. The mathematical model of this
system was then tested with additional experiments, including some new antibiotic regimens
where daily doses were no longer fixed. The model was shown to perform well in these subse-
quent experiments, and hence provides a useful new approach for researchers investigating the
optimisation of antibiotic therapy.
The second aim of this study was to apply an advanced computational search technique, a
Genetic Algorithm (GA), to this model to find optimal antibiotic dosage regimens that maxi-
mised host survival, while also minimising total antibiotic usage. In searching for the optimal
regimen, we relaxed the commonly made assumptions of fixed doses (where each dose is, say,
X mg) at fixed intervals (e.g. every 24 h)–the widened search space of possible treatments
makes the application of machine learning algorithms essential. When using a fixed total anti-
biotic dose of 0.9 mg, the best two-dose regimen was to apply 0.54 mg at 2 h and 0.36 mg at 11
h, giving a host survival rate of 0.795. This only increased slightly to 0.803 with a four-dose reg-
imen. However, both of these were predicted to be significantly greater survival than adminis-
tering all 0.9 mg in a single dose at 2 h. When aiming to minimise the total quantity of
antibiotic used while maximising host survival, all the treatments found (including those in
Table 4) show a similar pattern: the first dose is the largest dose, with many of the subsequent
doses decreasing thereafter. Many of the treatment durations were relatively short, with the
final dose being applied before the 24 h mark (Table 4). Here, the treatment intervals were rela-
tively consistent; for example, in with antibiotic being administered at 2 h, 9 h and 17 h
(Table 4, row 1) or 2 h, 7 h, 12 h and 17 h (Table 4, row 8). Treatment intervals could therefore
be an important, yet understudied area, with few studies of their effect on survival [50] or
development of resistance [51]. There was also an appearance of possible additional trade-offs:
for example, in reducing the maximum concentration of any individual doses required an
increase in the total quantity of antibiotic used and an increase in treatment duration; similarly
shorter dosage regimens appeared to increase the total antibiotic required and increased the
individual dosage sizes. A further study exploring these trade-offs, carrying out a multi-objec-
tive optimisation approach with the four objectives in Table 4, along with maximising host sur-
vival, is certainly worthy of attention. Furthermore, the mathematical model was
parameterised using a standard GA; however, when parameters are encoded as real numbers
we can apply modern evolutionary algorithms that specialise in the continuous domain, such
as Differential Evolution (DE) [52–53] and Covariance Matrix Adaptation Evolution Strategies
(CMA-ES) [54–55]. It may be possible that these methods can produce improved solutions in
shorter computational time, which would be an interesting follow-up study.
Significantly, this present study provides further evidence supporting the previous theoreti-
cal results that optimal dosage patterns for antibiotics follow a tapering pattern [29–30]. Given
that the tapered treatment patterns in this present study were derived from a biologically vali-
dated model, it provides evidence that further research into this observation is needed. Obvi-
ously, the next step would be to validate these optimal treatments in follow-up biological
experiments, directly testing conventional fixed-dose treatments against the optimal tapered
treatments and evaluating host survival across time. Furthermore, this present study focused
on the single outcome of host survival; however, future studies could integrate further benefi-
cial outcomes such as the risk associated with selecting for antibiotic-resistant strains [56–58].
Our results also reinforce previous findings in humans, including studies that have shown
that shorter treatment regimens can be effective in treating bacterial infections [59–60] and
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the use of initial high loading dose treatments being beneficial in treating patients in critical
care medicine [61]. Interestingly, tapered regimens are effective when treating infections
caused by Clostridium difficile [62–63]; however, the use of tapered regimens has resulted in
sub-optimal performance in bacterial clearance in some previous infection studies [35,64]
underlining the importance of deriving an optimal tapered strategy.
The duration under which a bacterium is exposed to antibiotics increases the likelihood of
resistance developing [65]. The selection of current treatment durations is relatively arbitrary,
albeit with supporting data from pharmacokinetic and pharmacodynamics trials, to ensure thera-
peutic concentrations of antibiotic are maintained in the host, and several studies have indicated
that shorter treatment regimens can be just as effective [66–68]. By altering the interval between
the constant doses, the GA produced treatment regimens that were shorter and showed little
change in the total quantity of antibiotic used. Shorter treatment durations have been identified
as being as effective as longer durations in treating a number of bacterial diseases [60,67,69], indi-
cating that current treatment guidelines, while effective, may not be the optimal way to adminis-
ter antibiotics. In addition, exposing the environment to larger quantities of antibiotic can
increase the abundance of resistant bacteria [70–71]. Optimal antibiotic treatments may also be
highly dependent on the current quantity of the target bacterial cells present in the host [72–76],
and it would be interesting to see how well the optimal treatments would perform across popula-
tions of individuals where variation in drug metabolism would play a significant role.
The conventional treatment regimen of a standard dose administered at equal intervals in
time is appealing to both manufacturers and patients. However, to increase the effectiveness of
antibiotics may require a move away from these conventional regimens. Changing the interval
between doses of antibiotics would be more preferable for manufacturers, as the doses of anti-
biotic remain constant and a single, standard product is manufactured. This shifts the burden
of responsibility to adhere to the new regimes more to the prescriber and the patient. Altering
the quantities of antibiotics given at set time intervals is another approach that could be effec-
tive, and in such a scenario different doses are prepared by the manufacturer for administra-
tion during the course of treatment. The constant time interval between doses is probably
simpler for the patient to comply and, interestingly, patient compliance rates are greatest
(almost 100%) for daily doses [77–78]. In the most complex scenario, both the quantities of
antibiotic given and the timings of each treatment during therapy are altered for an optimal
outcome. Unfortunately, lack of patient compliance remains a common problem [79–80] and
much further work is needed before changes to conventional treatment regimens could be
translated to the clinic. Of course, this would include the complete involvement of stakeholders
and a full understanding and consent around acceptable levels of safety and risk, particularly
the implications of inadvertently deviating from an optimised treatment. In this regard, it may
be in veterinary medicine where significant gains may be achieved more quickly.
With the increase in antibiotic resistant bacteria, research has begun to examine the effec-
tiveness of using multiple antibiotics, either sequentially or together in combinations [81–82].
Still, there is a need to ensure single antibiotics are used in an optimal manner, as this is
another key approach that may deliver considerable benefit to patients. The findings of this
present study highlight the potential amendments that could be made to single daily fixed-
dose antibiotic treatment regimens to increase their efficacy, thus reducing the health and eco-
nomic burdens associated with bacterial infections.
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